PMV Pharmaceuticals (PMVP) EBT (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly EBT came in at -$18.0 million in Q1 2026, up 8.12% YoY from -$16.7 million in Q1 2025, and little changed on a QoQ basis from -$18.0 million in Q4 2025.
PMV Pharmaceuticals (PMVP) EBT (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of EBT data on file, last reported at -$18.0 million in Q1 2026.
- Quarterly EBT rose 8.12% year-over-year to -$18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$78.3 million (up 1.17% YoY) and the FY2025 annual result came in at -$79.9 million, down 6.72% from the prior year.
- EBT was little changed at -$18.0 million in Q1 2026, from -$18.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$15.3 million in Q1 2024 to a low of -$23.1 million in Q4 2024.
- A 5-year average of -$18.5 million and a median of -$18.2 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT plunged 58.92% — and 2025, when it climbed 21.92%.
- Tracing PMVP's EBT over 5 years: stood at -$19.3 million in 2022, then rose by 18.55% to -$15.8 million in 2023, then plunged by 46.58% to -$23.1 million in 2024, then rose by 21.92% to -$18.0 million in 2025, then declined by 0.02% to -$18.0 million in 2026.
- The last three EBT figures came in at -$18.0 million (Q1 2026), -$18.0 million (Q4 2025), and -$21.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | -18.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.04 Mn |
| Dec 31, 2025 | -18.03 Mn |
| Sep 30, 2025 | -21.07 Mn |
| Jun 30, 2025 | -21.21 Mn |
| Mar 31, 2025 | -19.63 Mn |
| Dec 31, 2024 | -23.10 Mn |
| Sep 30, 2024 | -19.15 Mn |
| Jun 30, 2024 | -17.39 Mn |
| Mar 31, 2024 | -15.27 Mn |
| Dec 31, 2023 | -15.76 Mn |
| Sep 30, 2023 | -16.64 Mn |
| Jun 30, 2023 | -17.43 Mn |
| Mar 31, 2023 | -19.13 Mn |
| Dec 31, 2022 | -19.35 Mn |
| Sep 30, 2022 | -18.24 Mn |
| Jun 30, 2022 | -17.31 Mn |
| Mar 31, 2022 | -18.43 Mn |
| Dec 31, 2021 | -18.36 Mn |
| Sep 30, 2021 | -14.99 Mn |
| Jun 30, 2021 | -12.87 Mn |